Efruxifermin in non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the commonest causes of liver-related mortality and morbidity, with a predicted global prevalence of 30%. 1 Younossi ZM Golabi P Paik JM Henry A Van Dongen C Henry L The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77: 1335-1347 Crossref PubMed Scopus (188) Google Scholar This finding has fuelled extensive therapeutic research; however, there are no currently licensed therapies for NAFLD, with weight loss and lifestyle interventions as the mainstay of treatment. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialEfruxifermin improved liver fibrosis and resolved NASH over 24 weeks in patients with F2 or F3 fibrosis, with acceptable tolerability, supporting further assessment in phase 3 trials. Full-Text PDF Correction to Lancet Gastroenterol Hepatol 2023; 8: 1058–59Mahgoub S, Newsome PN. Efruxifermin in non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2023; 8: 1058–59—In the table of this Comment, the entry for Adverse events for the phase 2b HARMONY trial should read "Gastrointestinal upset (nausea and diarrhoea); adverse markers of bone turnover and high levels of anti-drug antibodies (significance unclear, requires long-term follow-up)" and the entry for Adverse events for the phase 2b ENLIVEN trial should read "Gastrointestinal upset (nausea and diarrhoea); increased appetite; anti-drug antibodies (significance unclear, requires long-term follow-up)". Full-Text PDF